Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.25 EUR | 0.00% | +2.48% | +3.12% |
04-16 | Svas Biosana increases profit in 2023; ex-dividend proposed | AN |
04-15 | Mib bullish; Leonardo on top | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Its low valuation, with P/E ratio at 9.48 and 7.3 for the ongoing fiscal year and 2024 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company shows low valuation levels, with an enterprise value at 0.61 times its sales.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.12% | 47.54M | - | ||
-2.31% | 187B | C+ | ||
-3.20% | 106B | C | ||
-5.04% | 66.9B | A | ||
+0.20% | 49.45B | B- | ||
+17.29% | 48B | B- | ||
+4.06% | 40.84B | B+ | ||
+2.07% | 26.48B | B | ||
+2.36% | 26.25B | A- | ||
+12.96% | 24.62B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SVS Stock
- Ratings Svas Biosana S.p.A.